ArticlePublic health challenges2023
African Medicines Agency: How it will change the landscape of medicines in Africa.
Article in Public health challenges, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Vaccine equity in Africa: a rapid review of policy, legal and governance frameworks to improve research and development.Frontiers in health services · 2026Pooled it
- MPOX outbreak in Africa: the urgent need for local manufacturing of the vaccine and decolonized health systems.BMC public health · 2025Pooled it
- Strengthening pharmacovigilance and regulatory capacity in Southern Africa (SPaRCS): achievements, experiences and lessons learned from a participatory action learning project.Frontiers in drug safety and regulation · 2026Article
- Adoption of international good manufacturing practices in the Nigerian pharmaceutical industry: promising results from a decade of investment.Journal of pharmaceutical policy and practice · 2026Review
- Strengthening Biomedical Research and Healthcare in Africa Through Localized Reagent Production.BioMed research international · 2026Review
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- Antiretroviral Use for HIV Prevention During Pregnancy: The Need to Strengthen Regulatory and Surveillance Systems in Africa.Drug safety · 2025Article
- Multipurpose prevention technologies for the prevention of unintended pregnancy, HIV, and other sexually transmitted infections: regulatory pathways and challenges.Frontiers in reproductive health · 2025Article
- Relationship between Prices and Quality of Essential Medicines from Different Manufacturers Collected in Cameroon, the Democratic Republic of the Congo, and Nigeria.The American journal of tropical medicine and hygiene · 2024Article
- Challenges of schistosomiasis control in Africa: The path ahead.Public health challenges · 2024Article
- African Medicines Agency: How it will change the landscape of medicines in Africa.Public health challenges · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The African continent, with a population of about 1.2 billion, faces limited access to safe, high-quality and effective medicine, resulting in a disproportionate disease burden. However, the scarcity of pharmaceuticals has been a significant problem for decades. The need to scale up local production of medicines in Africa is apparent, as over 70% of drugs available in the continent are imported. Africa's pharmaceutical manufacturing industry capacity is subpar due to inadequate production equipment and substandard operations. Inadequate pharmaceutical supplies encouraged the circulation of fake drugs, and the COVID-19 pandemic highlighted the dangers of the continent's reliance on foreign supplies. Africa's porous borders create ease for drug counterfeiting, with little likelihood of detection once in the supply chain. The African Medicines Agency (AMA) was founded to model the European Medicines Agency to enhance regional drug production, regulation and patient access. The African Union's AMA is a specialized health organization tasked with enhancing regulatory harmonization of medicines, particularly in pharmaceutical production, to increase access to high-quality medications across the continent. Africa's healthcare industry, particularly domestic pharmaceutical manufacturing, will be a significant economic engine for the continent over the next 5 years. The establishment of AMA is a call to action for governments and regulators to enable Africa to manufacture 60% of the vaccines needed on the continent by 2040.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.